- Home
- MGTX vs GBLI Comparison
MGTX vs GBLI Comparison
Compare MGTX & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- GBLI
- Stock Information
- Founded
- MGTX 2015
- GBLI 2016
- Country
- MGTX United States
- GBLI United States
- Employees
- MGTX N/A
- GBLI N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- GBLI Property-Casualty Insurers
- Sector
- MGTX Health Care
- GBLI Finance
- Exchange
- MGTX Nasdaq
- GBLI Nasdaq
- Market Cap
- MGTX 479.9M
- GBLI 476.1M
- IPO Year
- MGTX N/A
- GBLI 2003
- Fundamental
- Price
- MGTX $6.26
- GBLI $35.44
- Analyst Decision
- MGTX Strong Buy
- GBLI
- Analyst Count
- MGTX 2
- GBLI 0
- Target Price
- MGTX $23.50
- GBLI N/A
- AVG Volume (30 Days)
- MGTX 337.9K
- GBLI 5.1K
- Earning Date
- MGTX 03-13-2025
- GBLI 03-12-2025
- Dividend Yield
- MGTX N/A
- GBLI 4.03%
- EPS Growth
- MGTX N/A
- GBLI 90.04
- EPS
- MGTX N/A
- GBLI 2.92
- Revenue
- MGTX $13,929,000.00
- GBLI $442,500,000.00
- Revenue This Year
- MGTX N/A
- GBLI N/A
- Revenue Next Year
- MGTX $1,391.84
- GBLI $8.39
- P/E Ratio
- MGTX N/A
- GBLI $11.91
- Revenue Growth
- MGTX 108.24
- GBLI N/A
- 52 Week Low
- MGTX $3.85
- GBLI $27.47
- 52 Week High
- MGTX $7.37
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- MGTX 53.41
- GBLI 49.88
- Support Level
- MGTX $5.66
- GBLI $33.12
- Resistance Level
- MGTX $6.12
- GBLI $36.51
- Average True Range (ATR)
- MGTX 0.39
- GBLI 0.73
- MACD
- MGTX -0.02
- GBLI -0.17
- Stochastic Oscillator
- MGTX 62.26
- GBLI 62.70
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.